Indications for Orlistat 120 mg Capsules
Orlistat 120 mg is indicated as an adjunct to a reduced-calorie, low-fat diet and exercise program for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight adults (BMI ≥28 kg/m²) who have weight-related complications such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea 1.
Primary Indication
Orlistat is FDA-approved for the treatment of obesity in adults aged 18 years and older. The medication works by inhibiting gastrointestinal lipase, thereby preventing absorption of approximately 30% of dietary fat 1, 2.
Specific Patient Criteria:
- BMI ≥30 kg/m² (obesity) in otherwise healthy adults
- BMI ≥28 kg/m² (overweight) with at least one obesity-related comorbidity:
- Hypertension
- Type 2 diabetes mellitus
- Dyslipidemia/hyperlipidemia
- Obstructive sleep apnea
Important Clinical Context and Guideline Recommendation
The 2022 AGA Clinical Practice Guideline actually recommends AGAINST the routine use of orlistat for obesity management 3. This conditional recommendation is based on moderate-certainty evidence showing:
- Modest weight loss: only 2.78% total body weight loss (approximately 2.81 kg) compared to placebo 3
- High rate of gastrointestinal adverse effects leading to treatment discontinuation (RR 2.86 for GI-related discontinuation) 3
- Rare but serious risk of liver injury (13 reported cases of liver failure) 3
When Orlistat May Still Be Considered:
The guideline acknowledges that orlistat may be reasonable for "a small but meaningful minority of patients who place a higher value on the modest amount of weight loss and lower value on the possibility of GI adverse effects" 3.
Contraindications (When NOT to Use):
- Organ transplant recipients (orlistat interferes with immunosuppressive medications) 1
- Chronic malabsorption syndromes 1
- Cholestasis 1
- Allergy to orlistat or its components 1
- Pregnancy or breastfeeding 1
- Patients taking cyclosporine 1
Relative Contraindications:
- History of gallbladder disease, kidney stones, or pancreatitis (requires physician consultation) 1
- Patients with chronic diarrhea, celiac disease, inflammatory bowel disease, or history of bariatric surgery 3
Dosing and Administration Requirements:
- 120 mg three times daily with each fat-containing meal (or up to 1 hour after) 1
- Can omit dose if meal is very low in fat 3
- Must be combined with:
Expected Outcomes:
- Most weight loss occurs within the first 6 months 1
- Typical weight loss: 5-10 pounds over 6 months in clinical trials 1
- For every 5 pounds lost from diet alone, orlistat adds approximately 2-3 pounds additional loss 1
- 71% increased likelihood of achieving ≥5% total body weight loss 3
- 94% increased likelihood of achieving ≥10% total body weight loss 3
Critical Monitoring and Drug Interactions:
Medications requiring dose adjustment or increased monitoring:
- Warfarin (anticoagulants) - may alter INR 1
- Levothyroxine - separate by at least 4 hours 3
- Cyclosporine - contraindicated 1
- Antiepileptic medications - may reduce seizure control 1
- Antiretroviral medications (HIV drugs) 1
- Amiodarone 1
Monitor for signs of liver injury: jaundice, dark urine, loss of appetite, severe abdominal pain 1
Common Pitfalls to Avoid:
- Failing to counsel about GI side effects: Patients must understand that oily spotting, loose stools, fecal urgency, and potential fecal incontinence are common, especially with high-fat meals 3
- Not prescribing multivitamin supplementation: Fat-soluble vitamin deficiency is a real risk 3, 1
- Using in patients with malabsorptive conditions: This will worsen malabsorption 3
- Expecting dramatic weight loss: Set realistic expectations of modest (3-4 kg) additional weight loss beyond diet alone 3